|
MEGF9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.499899999997E-05 |
| Normal-vs-Stage3 |
1.65378821748163E-12 |
| Normal-vs-Stage4 |
9.71159996865367E-09 |
| Stage1-vs-Stage2 |
1.012150E-01 |
| Stage1-vs-Stage3 |
9.089800E-01 |
| Stage1-vs-Stage4 |
3.985000E-01 |
| Stage2-vs-Stage3 |
1.686040E-01 |
| Stage2-vs-Stage4 |
4.813800E-01 |
| Stage3-vs-Stage4 |
4.951400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.768880E-04 |
| Normal-vs-Asian |
1.22679999492448E-08 |
| Caucasian-vs-AfricanAmerican |
4.253400E-01 |
| Caucasian-vs-Asian |
2.141600E-01 |
| AfricanAmerican-vs-Asian |
9.215000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62814206561279E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
3.213900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
2.06939998470546E-09 |
| Normal-vs-Age(81-100Yrs) |
9.277600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.647800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.513600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.949700E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.026840E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.983900E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.363000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.813800E-01 |
| Classical-VS-Follicular |
1.18629994716457E-10 |
| Classical-VS-Other |
1.127170E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
2.41729999999052E-05 |
| Tall-VS-Other |
4.712200E-02 |
| Tall-VS-Normal |
1.28989996461826E-09 |
| Follicular-VS-Other |
7.900800E-01 |
| Follicular-VS-Normal |
2.31379999999781E-05 |
| Other-VS-Normal |
5.819600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62458935193399E-12 |
| Normal-vs-N1 |
4.67649999835729E-08 |
| N0-vs-N1 |
4.205200E-01 |
|
|
